- Sections
- C - Chimie; métallurgie
- C07D - Composés hétérocycliques
- C07D 209/48 - Iso-indoles; Iso-indoles hydrogénés avec des atomes d'oxygène en positions 1 et 3, p.ex. phtalimide
Détention brevets de la classe C07D 209/48
Brevets de cette classe: 758
Historique des publications depuis 10 ans
|
77
|
66
|
69
|
61
|
51
|
50
|
40
|
33
|
37
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| LG Chem, Ltd. | 17620 |
19 |
| Amgen Inc. | 3894 |
12 |
| Cancer Research Technology Limited | 525 |
11 |
| FUJIFILM Corporation | 28467 |
10 |
| The Scripps Research Institute | 1353 |
8 |
| SHPP Global Technologies B.V. | 1059 |
8 |
| Siemens Medical Solutions USA, Inc. | 1542 |
7 |
| ExxonMobil Chemical Patents Inc. | 4118 |
7 |
| Ranbaxy Laboratories Limited | 364 |
7 |
| Boehringer Ingelheim International GmbH | 4762 |
6 |
| Syngenta Participations AG | 3039 |
6 |
| Wisconsin Alumni Research Foundation | 3819 |
6 |
| Celgene Corporation | 1498 |
6 |
| SABIC Global Technologies B.V. | 4186 |
6 |
| The Trustees of Princeton University | 1162 |
6 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2827 |
6 |
| Vectus Biosystems Limited | 35 |
6 |
| Zeon Corporation | 3986 |
6 |
| Massachusetts Institute of Technology | 9903 |
5 |
| Astex Therapeutics Limited | 257 |
5 |
| Autres propriétaires | 605 |